These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23759658)

  • 21. Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells.
    Fan P; Zhang B; Kuroki S; Saku K
    Circ J; 2004 Nov; 68(11):1061-6. PubMed ID: 15502389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
    Takayama T; Wada A; Tsutamoto T; Ohnishi M; Fujii M; Isono T; Horie M
    Circ J; 2004 Nov; 68(11):1067-75. PubMed ID: 15502390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
    Hiro T; Kimura T; Morimoto T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Kimura K; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    J Am Coll Cardiol; 2009 Jul; 54(4):293-302. PubMed ID: 19608026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
    Sanada S; Asanuma H; Minamino T; Node K; Takashima S; Okuda H; Shinozaki Y; Ogai A; Fujita M; Hirata A; Kim J; Asano Y; Mori H; Tomoike H; Kitamura S; Hori M; Kitakaze M
    Circulation; 2004 Oct; 110(15):2143-9. PubMed ID: 15451788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
    Stender S; Budinski D; Hounslow N
    Eur J Prev Cardiol; 2013 Feb; 20(1):29-39. PubMed ID: 22345687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
    Pelliccia F; Rosano G; Marazzi G; Vitale C; Spoletini I; Franzoni F; Speziale G; Polacco M; Greco C; Gaudio C
    Circ J; 2014; 78(3):679-84. PubMed ID: 24389597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitavastatin suppresses formation and progression of cerebral aneurysms through inhibition of the nuclear factor kappaB pathway.
    Aoki T; Kataoka H; Ishibashi R; Nakagami H; Nozaki K; Morishita R; Hashimoto N
    Neurosurgery; 2009 Feb; 64(2):357-65; discussion 365-6. PubMed ID: 19190463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia.
    Yagi S; Akaike M; Aihara K; Iwase T; Ishikawa K; Yoshida S; Sumitomo-Ueda Y; Kusunose K; Niki T; Yamaguchi K; Koshiba K; Taketani Y; Tomita N; Yamada H; Soeki T; Wakatsuki T; Matsumoto T; Sata M
    Am J Cardiol; 2011 Jun; 107(11):1644-9. PubMed ID: 21458773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiovascular prevention and pitavastatin].
    Kayıkçıoğlu M
    Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):8-12. PubMed ID: 28952472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
    Harada-Shiba M; Arisaka O; Ohtake A; Okada T; Suganami H;
    J Atheroscler Thromb; 2016; 23(1):48-55. PubMed ID: 25891210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
    Stender S; Budinski D; Gosho M; Hounslow N
    Eur J Prev Cardiol; 2013 Feb; 20(1):40-53. PubMed ID: 22679249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.
    Ichimura K; Matoba T; Koga JI; Nakano K; Funamoto D; Tsutsui H; Egashira K
    Int Heart J; 2018 Nov; 59(6):1432-1444. PubMed ID: 30369578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
    Yoshitomi Y; Ishii T; Kaneki M; Tsujibayashi T; Sakurai S; Nagakura C; Miyauchi A
    J Atheroscler Thromb; 2006 Apr; 13(2):108-13. PubMed ID: 16733299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
    Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
    N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis.
    Lim JW; Jeong HS; Hong SJ; Kim HJ; Kim YC; Kang BG; Jeon SM; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW
    Heart Vessels; 2019 Jan; 34(1):62-73. PubMed ID: 30047013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitavastatin: A Review in Hypercholesterolemia.
    Hoy SM
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):157-168. PubMed ID: 28130659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Statins Modify the Wound Healing Process After Myocardial Infarction?
    Hasegawa H
    Int Heart J; 2017 Aug; 58(4):472-474. PubMed ID: 28717118
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design.
    Watanabe T; Miyamoto T; Miyasita T; Shishido T; Arimoto T; Takahashi H; Nishiyama S; Hirono O; Matsui M; Sugawara S; Ikeno E; Miyawaki H; Akira F; Kubota I
    J Cardiol; 2014 Sep; 64(3):236-9. PubMed ID: 24503140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.